Charles Large, PhD, is CEO and Founder of Autifony Therapeutics, a clinical stage company based in the UK. Previously he was Director of Molecular and Cellular Biology within the Neuroscience Centre of Excellence for Drug Discovery at GlaxoSmithKline. Dr Large has over 30 years of experience in drug discovery and is an expert on drugs that modulate voltage-gated ion channels.
Søren Lemonius is Managing General Partner and one of the three co-founders of Sunstone. Søren has particular focus on Investor relations and therapeutics. Søren has 20 years’ experience from corporate management in R&D-intensive companies. As Innovation Manager at FOSS Analytical (a food diagnostics company), Søren successfully implemented new analytical technologies. Prior to joining Sunstone, Søren served as Chief Technology Officer at Danionics (an electronic component company) where he participated in developing the company from a private, 30-employee, venture-backed technology company to a EUR +27 million revenue, +300-employee, listed company. Søren holds a master’s degree in Experimental Cell Biology from the University of Southern Denmark.
Before founding Sound Bioventures, Casper was a Senior Partner at Lundbeckfonden Ventures, where he worked for 12 years, and led investments and served as a member of the board of directors in companies including: Sanifit, Aura Biosciences, Spero Therapeutics, Nexstim, Biomup. Prior to that, he was CEO of the venture backed diagnostics company ilochip A/S. Before that Casper worked in the pharmaceutical industry for 15 years in a range of different positions in R&D, Project Management, Sourcing, Quality Assurance, and Business Development & Strategy, for Lundbeck, Novo Nordisk and Niels Clauson-Kaas. While working at Lundbeck, Casper was part of spinning Veloxis out of Lundbeck, and served on the board of the Lundbeck Foundation.
Dr. Koistinaho is a Partner at Innovestor Life Science Fund and a biotech commercialization professional with over 20 years of experience in drug discovery, start-ups and technology licensing. She has co-founded 3 biotech start-ups based on her own academic discoveries and has deep experience in pharmaceutical discovery and development, IPR generation and prosecution, fundraising, out-licensing and other corporate transactions. She has also served as the COO of technology transfer operations at the University of Helsinki. Milla Koistinaho is a founding partner of a new 90m EUR venture capital fund, Innovestor Life Science, investing in Seed to Series A stage, strong health sciences based companies in the Nordics and Baltics. Milla also holds several non-executive directorships in therapeutics development companies in the Nordics and serves as a member of the commercialization advisory board of University of Helsinki.
Fredrik is Venture Partner at Industrifonden. He has a PhD in medicinal chemistry and 20 years of experience in drug development. Previously, he has worked at Pharmacia, Biovitrum, OT Chemistry, Recipharm and Oncopeptides and has founded and operated a handful companies within Life Science. He is currently CEO and board member of OT Pharmaceuticals AB. Chairman of the board of Synartro AB and boardmember of AnaCardio AB, Sprint Bioscience (publ) and Guard Therapeutics (publ). In addition he is scientific advisor to Akthelia Pharmaceuticals.
Susanne Stuffers is a founding partner and CEO of P53 Invest AS. She has broad experience in healthcare and life sciences, covering the sector from several angles. Susanne was a management consultant in health care/life sciences at EY, served in medical and commercial roles in the pharmaceutical industry (Novartis), and has clinical practice as a resident in oncology. She worked with Arctic Securities (equity analyst), before joining forces with T.D. Veen to co-found and lead p53. She has served as a member of the board of directors in companies including Nykode Therapeutics AS, Arxx Therapeutics AS and Pacertool AS. Susanne holds an M.D. degree from the Erasmus University Rotterdam, Netherlands, and a Ph.D. degree in cancer biomedicine from the Norwegian Radiumhospital.
Simon Molgaard, PhD, is co-inventor of key Teitur patents. Author of key neuroscience publications over the last 10 years. Has led research, operations, financing and initiation of key collaborations for this project since 2015. Former visiting scientist at Mayo Clinic, US.
